ACE2 and COVID-19: Subsequently, the inhibitory effects of some natural βC analogues have been documented against some targets implicated in the pathogenesis and treatment of COVID-19 including the viral main proteases, spike glycoprotein, nsp9 and host angiotensin-converting enzyme 2 (ACE2) as well as the transmembrane protease serine 2 (TMPRSS2) (Chakravarti et al., 2021; Parmar et al., 2021).